Previous 10 | Next 10 |
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $2.7...
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced the pricing of the previously announced underwritten public offering of 10,000,000 shares of its common stock at a price to the pub...
Exicure (NASDAQ: XCUR ) down 7.09% AH as the company announces underwritten public offering; More news on: Exicure, Inc., Healthcare stocks news, Read more ...
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Exicure intends to gr...
2020 should be another favorable year for healthcare investing, though the gains thus far in 2019 should necessitate greater selectivity. The overriding investment theme in healthcare, in my opinion, is the fact that the dual tailwinds of the aging of the population and the obesity epidemic (b...
- Exicure to collaborate with Friedreich’s Ataxia Research Alliance (FARA) - Hank Paulson, MD, PhD and Susan Perlman, MD, added to Scientific Advisory Board Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nuc...
Market Volatility Has Traders Watch Penny Stocks Investing in penny stocks can often prove to be highly rewarding for investors. Over the years, plenty of people have managed to make fortunes by picking the best penny stocks to buy. However, one needs to watch the market closely as well to f...
- Phase 1b/2 dose escalation trial of AST-008 shows tolerability of Exicure drug candidate - Preliminary data show signs of activity in patients with Merkel cell carcinoma - Exicure to proceed to Phase 2 study in Merkel cell carcinoma Exicure, Inc. (NASDAQ:XCUR), the pioneer...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 133 weeks of public selections as part of this ongoing live forward-testing. ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
-3.60% Change Percent:
Exicure Inc. Company Name:
XCUR Stock Symbol:
OTCMKTS Market:
Exicure Inc. Website:
A look at the top 10 most actives in the United States Agape ATP Corporation (ATPC) rose 112.1% to $0.3033 on volume of 62,336,784 shares Warrantee Inc. (WRNT) rose 27.8% to $0.372 on volume of 55,635,565 shares Adial Pharmaceuticals Inc (ADIL) rose 110.3% to $2.2295 on volume of 54,549,4...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspe...